RIBOZYME AND OMICS

Announcement / News

News

Rznomics to Participate in ‘BIO-Europe 2025’ to Expand Global Collaborations

  • 작성자
    관리자
  • 날짜
    2025-11-04
Rznomics Inc. announced on the 3rd November that it will officially participate in BIO-Europe 2025, a premier global biopharma conference held in Vienna, Austria, from November 3 to 5. BIO-Europe is the largest partnering event in Europe, bringing together over 5,000 industry professionals from more than 60 countries.

During the event, Rznomics plans to showcase its proprietary RNA editing platform and gene therapy development strategies. The company will actively seek opportunities for licensing agreements and co-development collaborations through strategic partnering meetings with global pharmaceutical companies, biotech firms, and investors.

Rznomics has garnered significant attention within international academic and industrial circles for its differentiated technological platform: "Trans-splicing Ribozyme-based RNA Editing Therapeutics." In May, the company proved its technological innovation and global competitiveness by signing a research collaboration and licensing agreement with the U.S. pharmaceutical giant Eli Lilly and Company, with a total deal value reaching approximately KRW 1.9 trillion (USD 1.3 billion).

As global interest in RNA-based therapeutic technologies continues to rise, Rznomics intends to discuss various collaboration models, including platform-based out-licensing and joint R&D, while further refining its plans for global market expansion through these high-level meetings.

"Since our major licensing deal with Eli Lilly, interest from leading global companies has surged significantly," said Sungwoo Hong, Vice President of Rznomics, who is attending the event. "Our participation in BIO-Europe 2025 will serve as a catalyst to accelerate additional licensing deals and expand our collaborative network with global industry leaders."
PREV
Rznomics Receives Preliminary KOSDAQ Listing Approval
LIST
LIST
NEXT
Rznomics to Lead Next-Generation Gene Therapy with Trans-splicing Ribozyme Platf...